516
Participants
Start Date
July 6, 2023
Primary Completion Date
February 7, 2025
Study Completion Date
March 14, 2025
Solriamfetol 150 mg
Solriamfetol tablets, taken once daily
Solriamfetol 300 mg
Solriamfetol tablets, taken once daily
Placebo
Placebo tablets, taken once daily
Clinical Research Site, New York
Clinical Research Site, Mount Kisco
Clinical Research Site, Media
Clinical Research Site, Raleigh
Clinical Research Site, North Charleston
Clinical Research Site, Marietta
Clinical Research Site, Jacksonville
Clinical Research Site, Gainesville
Clinical Research Site, Orlando
Clinical Research Site, Miami Lakes
Clinical Research Site, Doral
Clinical Research Site, Lauderhill
Clinical Research Site, Clermont
Clinical Research Site, Memphis
Clinical Research Site, Cincinnati
Clinical Research Site, Kettering
Clinical Research Site, Saint Charles
Clinical Research Site, Overland Park
Clinical Research Site, Lincoln
Clinical Research Site, Oklahoma City
Clinical Research Site, Dallas
Clinical Research Site, Dallas
Clinical Research Site, Bellaire
Clinical Research Site, San Antonio
Clinical Research Site, Austin
Clinical Research Site, Colorado Springs
Clinical Research Site, Draper
Clinical Research Site, Las Vegas
Clinical Research Site, Las Vegas
Clinical Research Site, Torrance
Clinical Research Site, Encino
Clinical Research Site, Sherman Oaks
Clinical Research Site, Riverside
Clinical Research Site, Newport Beach
Clinical Research Site, Santa Ana
Clinical Research Site, Garden Grove
Clinical Research Site, Walnut Creek
Clinical Research Site, Everett
Clinical Research Site, Boston
Clinical Research Site, Berlin
Clinical Research Site, Cherry Hill
Clinical Research Site, Princeton
Lead Sponsor
Axsome Therapeutics, Inc.
INDUSTRY